CTX-712 |
| Catalog No.GC65023 |
Le CTX-712 est un puissant inhibiteur de la kinase de type cdc2 (CLK). Le CTX-712 inhibe l'activité de la kinase CLK et inhibe ainsi la survie au cancer et la croissance des cellules cancéreuses. Le CTX-712 a le potentiel pour la recherche sur les maladies cancéreuses (extrait du brevet JPWO2017188374A1, composé 286).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2144751-78-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CTX-712 is a potent inhibitor of cdc2-like kinase (CLK). CTX-712 inhibits CLK kinase activity, and thus inhibits cancer survival and cancer cell growth. CTX-712 has the potential for the research of cancer disease (extracted from patent JPWO2017188374A1, compound 286)[1].
[1]. Fused heterocyclic compounds. Patent JPWO2017188374A1.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *